Free Trial

Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

Alnylam Pharmaceuticals logo
$447.36 +0.96 (+0.21%)
As of 03:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)

Advanced

Key Stats

Today's Range
$446.30
$451.63
50-Day Range
$320.52
$482.13
52-Week Range
$205.87
$484.21
Volume
378,897 shs
Average Volume
974,831 shs
Market Capitalization
$58.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$439.58
Consensus Rating
Moderate Buy

Company Overview

Alnylam Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

ALNY MarketRank™: 

Alnylam Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 303rd out of 743 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 24 buy ratings, 4 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Alnylam Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Alnylam Pharmaceuticals has been the subject of 22 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Alnylam Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($1.70) to $0.89 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alnylam Pharmaceuticals is -181.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alnylam Pharmaceuticals is -181.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Alnylam Pharmaceuticals has a P/B Ratio of 862.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Alnylam Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    3.07% of the float of Alnylam Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alnylam Pharmaceuticals has recently increased by 15.74%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Alnylam Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Alnylam Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.07% of the float of Alnylam Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alnylam Pharmaceuticals has recently increased by 15.74%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Alnylam Pharmaceuticals has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Alnylam Pharmaceuticals this week, compared to 21 articles on an average week.
  • Search Interest

    Only 16 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,968,256.00 in company stock.

  • Percentage Held by Insiders

    Only 1.20% of the stock of Alnylam Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alnylam Pharmaceuticals' insider trading history.
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALNY Stock News Headlines

Dividend Reset = Opportunity to Grab This 9.2% Yield at a Discount
...
Early Activity. Real Signal.
A repeatable signal just triggered—one we’ve seen before major moves. This time, it’s pointing to a small-cap flying under nearly everyone’s radar. Daily Edge Report just released a free alert with full details, including the company name and why this setup stands out.tc pixel
See More Headlines

ALNY Stock Analysis - Frequently Asked Questions

Alnylam Pharmaceuticals' stock was trading at $235.31 at the start of the year. Since then, ALNY shares have increased by 90.6% and is now trading at $448.4650.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings data on Thursday, July, 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals's revenue for the quarter was up 17.3% on a year-over-year basis.
Read the conference call transcript
.

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and The RMR Group (RMR).

Company Calendar

Last Earnings
7/31/2025
Today
9/29/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALNY
CIK
1178670
Employees
2,230
Year Founded
2002

Price Target and Rating

High Price Target
$583.00
Low Price Target
$220.00
Potential Upside/Downside
-1.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
28 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$278.16 million
Net Margins
-12.96%
Pretax Margin
-15.42%
Return on Equity
-273.52%
Return on Assets
-7.39%

Debt

Debt-to-Equity Ratio
4.10
Current Ratio
2.80
Quick Ratio
2.75

Sales & Book Value

Annual Sales
$2.25 billion
Price / Sales
26.06
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.52 per share
Price / Book
859.72

Miscellaneous

Outstanding Shares
131,080,000
Free Float
129,506,000
Market Cap
$58.60 billion
Optionable
Optionable
Beta
0.32

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ALNY) was last updated on 9/29/2025 by MarketBeat.com Staff
From Our Partners